Recombinant Human CD96 Fc Chimera Protein, CF

When Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD) is immobilized at 1 μg/mL, 100 μL/well, Recombinant Human CD96 Fc Chimera (Catalog # 9360-CD) binds with an ED50 of 0.3-1.8 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD96 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD) is immobilized at 1 μg/mL, 100 μL/well, the concentration of Recombinant Human CD96 Fc Chimera that produces 50% of the optimal binding response is 0.3-1.8 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CD96 protein
  

  Human CD96 (Lys25-Met519) Accession # P40200-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

  
  

• Accession #: P40200-1
• N-terminal Sequence: Lys25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 81 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 131 - 160 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD96 Fc Chimera Protein, CF

• CD96 antigenMGC22596
• CD96 molecule
• CD96
• DKFZp667E2122
• T cell-activated increased late expression protein
• TACTILE
• TACTILEincreased late expression
• T-cell surface protein tactile

Background

Human CD96, also known as Tactile (T cell-activated increased late expression), is a 160 kDa type I transmembrane glycoprotein of the Ig superfamily that shows peak expression 6-9 days after activation of T, NK, and a subpopulation of B cells (1, 2). CD96 is also frequently expressed on acute myeloid leukemia and myelodysplastic stem cells (3, 4). It is expressed on CD4⁺ and CD8⁺ T cells, plus NK cells and select B cells (5). Low expression of adhesive human CD96 is a rare cause of C syndrome, a set of developmental anomalies in cranial bone (trigonocephaly), skin and viscera, demonstrating a role for CD96 in development of these tissues (2, 6). Mature human CD96 is a 564 amino acid (aa), type I transmembrane glycoprotein. It contains a 498 aa extracellular region that includes three Ig-like domains. The two N-terminal domains are V-type, while the distal domain is a C-type structure.  Within the ECD, human CD96 shares 53% and 52% aa sequence identity with mouse CD96 and rat CD96, respectively (7). The ECD is highly N- and O-glycosylated (1). Humans express a splice variant with a 16 aa deletion in the second V-type domain, called CD96v2 (2). An 80 kDa soluble form is elevated in human serum during chronic hepatitis B (9). The most N-terminal Ig-like domain of human CD96 binds to CD155/PVR (poliovirus receptor), but CD96/CD155 interaction is species-specific (2, 7, 10). Mouse CD96 also binds nectin-1 (7). On NK cells, co-stimulatory CD96 and DNAM-1 (CD226) are thought to have paired activity with inhibitory TIGIT, all of which bind CD155 and various nectins (11, 12). CD96 can promote NK cell adhesion to, and killing of target cells, including tumors that express CD155 (10, 11).

1. Wang, P.L. et al. (1992) J. Immunol. 148:2600.
2. Meyer, D. et al. (2009) J. Biol. Chem. 284:2235.
3. Hosen, N. et al. (2007) Proc. Natl. Acad. Sci. USA 104:11008.
4. Xie, W. et al. (2010) Cytometry A 77:840.
5. Eriksson, E. M. et al. (2012) PLOS One 7:e51696.
6. Kaname, T. et al. (2007) Am. J. Hum. Genet. 81:835.
7. Seth, S. et al. (2007) Biochem. Biophys. Res. Commun. 364:959.
8. Protein Accession # BAE32358.
9. Gong, J. et al. (2008) Clin. Exp. Immunol. 155:207.
10. Fuchs, A. et al. (2004) J. Immunol. 172:3394.
11. Stanietsky, N. and O. Mandelboim (2010) FEBS Lett. 584:4895.
12. Xu, Z. and B. Jin (2010) Cell. Mol. Immunol. 7:11.

Publications for CD96 (9360-CD)(2)

Publications using 9360-CD

• P Fittje, A Hœlzemer, WF Garcia-Bel, S Vollmers, A Niehrs, K Hagemann, G Martrus, C Körner, F Kirchhoff, D Sauter, M Altfeld HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells Oncogene, 2022-06-24;18(6):e1010572. 2022-06-24 [PMID: 35749424] (Bioassay, Human)
• J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity Nature Communications, 2022-03-25;13(1):1606. 2022-03-25 [PMID: 35338135] (Flow Cytometry, Human)

Bioinformatics

• Uniprot:
  • P40200-1()